# GATA-3 Suppression by DNAzyme Modulates Interleukin-10 and Liver Injury Markers in db/db Mice

## TL;DR

This study shows that reducing GATA-3 in obese diabetic mice lowers liver damage and increases anti-inflammatory proteins, suggesting a potential new treatment for obesity-related diseases.

## Contribution

The study demonstrates that GATA-3 suppression using DNAzyme reduces liver injury and inflammation in db/db mice.

## Key findings

- GATA-3 suppression increased interleukin-10 levels in the liver and serum.
- High-dose DNAzyme reduced hepatocyte ballooning degeneration in obese mice.
- GATA-3 suppression did not alter fat distribution or organ weights significantly.

## Abstract

Obesity often leads to liver problems and inflammation, which can worsen conditions like type 2 diabetes. This study explores whether reducing the activity of an intracellular protein called GATA-3, which is involved in fat cell development and inflammation, might offer benefits. We treated obese diabetic mice with a special enzyme-based treatment that targets GATA-3. We found that the treatment did not change how fat was distributed in the body, but it did reduce signs of liver damage and increase levels of an anti-inflammatory protein called interleukin-10. Our results suggest that targeting GATA-3 could be a promising way to protect the liver and reduce inflammation in obesity-related diseases, potentially leading to new treatments for conditions like fatty liver disease and diabetes.

Obesity plays a crucial role in the progression of insulin resistance and type 2 diabetes which are related to inflammation and liver disease. GATA-3 is a transcription factor that is involved in adipogenesis and inflammation. Therefore, it could be a potential therapeutic target for obesity-associated metabolic disorders. This study aimed to examine the effects of GATA-3 suppression on body weight, fat depot redistribution, liver histopathology, and inflammatory markers in transgenic db/db obese mice. Male db/db mice received subcutaneous injections of GATA-3-specific DNAzyme (hgd40; 10 or 100 µg/mL), pioglitazone (as a positive control), or vehicle only (as a negative control), twice weekly for two weeks. Body weight, organ weights, liver histopathology, mRNA expression of selected genes and serum cytokine levels were assessed. GATA-3 expression was not region specific, and its suppression did not significantly affect fat depot distribution or organ weights. However, the low dose of hgd40 accelerated body weight gain transiently. It also increased Il10 mRNA expression in the liver and significantly increased IL-10 protein concentration in the serum. In addition, a high dose of hgd40 resulted in a marked decrease in hepatocyte ballooning degeneration. These findings suggest that GATA-3 suppression may modulate inflammation and liver injury in obesity, warranting further investigation into its therapeutic potential for obesity-related metabolic disorders.